Abstract
Introduction
Gliosarcomas are extremely rare malignant brain tumors, which can be classified as primary gliosarcoma (PGS) if the tumors arise de novo or secondary gliosarcoma (SGS) in patients who had previously been treated for glioblastoma. Given their rarity, it is unclear if PGS is clinically and genetically different from SGS. This meta-analysis aimed to investigate the clinicopathological features, prognostic survivals, and molecular profiles of these rare tumors.
Methods
We searched PubMed and Web of Science for relevant studies. Odds ratio (OR), hazard ratio (HR), and their 95% confidence intervals (CI) were pooled using the random-effect model.
Results
We included eight studies with 239 PGS and 79 SGS for meta-analyses. Compared to PGS, SGS occurred at a younger age and had lower rates of gross total resection and radiation therapy. Bevacizumab was more commonly administered in SGS. SGS patients had a significantly worse PFS (HR 0.60; 95% CI 0.40–0.89) and OS (HR 0.46; 95% CI 0.31–0.68) in comparison to PGS. The incidences of EGFR mutation, IDH mutation, and MGMT methylation were not statistically different between PGS and SGS.
Conclusion
Our results demonstrated that PGS and SGS had distinct clinicopathological profiles and prognoses but shared similar genetic profiles. This study facilitates our understanding of how these two malignant brain tumors behave clinically, but future studies will be required to elucidate the genetic pathways of PGS and SGS.
Similar content being viewed by others
Data availability
Not applicable.
References
Louis DN, Perry A, Wesseling P et al (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro-Oncology 23(8):1231–1251
Perry JR, Ang LC, Bilbao JM, Muller PJ (1995) Clinicopathologic features of primary and postirradiation cerebral gliosarcoma. Cancer 75(12):2910–2918
Frandsen S, Broholm H, Larsen VA et al (2019) Clinical characteristics of gliosarcoma and outcomes from standardized treatment relative to conventional glioblastoma. Front Oncol 9:1425
Hong B, Lalk M, Wiese B et al (2021) Primary and secondary gliosarcoma: differences in treatment and outcome. Br J Neurosurg 1:8
Jin MC, Liu EK, Shi S et al (2020) Evaluating surgical resection extent and adjuvant therapy in the management of gliosarcoma. Front Oncol 10:337
Lee D, Kang SY, Suh YL, Jeong JY, Lee JI, Nam DH (2012) Clinicopathologic and genomic features of gliosarcomas. J Neurooncol 107(3):643–650
Saadeh F, El Iskandarani S, Najjar M, Assi HI (2019) Prognosis and management of gliosarcoma patients: a review of literature. Clin Neurol Neurosurg 182:98–103
Cachia D, Kamiya-Matsuoka C, Mandel JJ et al (2015) Primary and secondary gliosarcomas: clinical, molecular and survival characteristics. J Neurooncol 125(2):401–410
Han SJ, Yang I, Tihan T, Chang SM, Parsa AT (2010) Secondary gliosarcoma: a review of clinical features and pathological diagnosis. J Neurosurg 112(1):26–32
Ohgaki H, Kleihues P (2013) The definition of primary and secondary glioblastoma. Clin Cancer Res 19(4):764–772
Ohgaki H, Kleihues P (2007) Genetic pathways to primary and secondary glioblastoma. Am J Pathol 170(5):1445–1453
Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7):e1000097
The Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm.
Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8:16
Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558
Amer A, Khose S, Alhasan H et al (2022) Clinical and survival characteristics of primary and secondary gliosarcoma patients. Clin Neurol Neurosurg 214:107146
Smith DR, Wu CC, Saadatmand HJ et al (2018) Clinical and molecular characteristics of gliosarcoma and modern prognostic significance relative to conventional glioblastoma. J Neurooncol 137(2):303–311
Ohgaki H, Dessen P, Jourde B et al (2004) Genetic pathways to glioblastoma: a population-based study. Cancer Res 64(19):6892–6899
Larjavaara S, Mäntylä R, Salminen T et al (2007) Incidence of gliomas by anatomic location. Neuro-Oncology 9(3):319–325
Zaki MM, Mashouf LA, Woodward E et al (2021) Genomic landscape of gliosarcoma: distinguishing features and targetable alterations. Sci Rep 11(1):18009
Vuong HG, Nguyen TQ, Ngo TNM, Nguyen HC, Fung KM, Dunn IF (2020) The interaction between TERT promoter mutation and MGMT promoter methylation on overall survival of glioma patients: a meta-analysis. BMC Cancer 20(1):897
Palmisciano P, Ferini G, Watanabe G et al (2022) Gliomas infiltrating the corpus callosum: a systematic review of the literature. Cancers 14(10):2507
Inserra F, Barone F, Palmisciano P et al (2022) Hypofractionated gamma knife radiosurgery: institutional experience on benign and malignant intracranial tumors. Anticancer Res 42(4):1851–1858
McAleer MF, Brown PD (2015) Therapeutic management of gliosarcoma in the temozolomide era. CNS Oncol 4(3):171–178
Kozak KR, Mahadevan A, Moody JS (2009) Adult gliosarcoma: epidemiology, natural history, and factors associated with outcome. Neuro-Oncology 11(2):183–191
Walker GV, Gilbert MR, Prabhu SS, Brown PD, McAleer MF (2013) Temozolomide use in adult patients with gliosarcoma: an evolving clinical practice. J Neurooncol 112(1):83–89
Acknowledgements
Not applicable.
Funding
This study received no funding support.
Author information
Authors and Affiliations
Contributions
HGV: conceptualization, data curation, formal analysis, investigation, methodology, project administration, software, validation, writing original, review. IFD: data curation, formal analysis, investigation, methodology, project administration, validation, review, editing, and sup ervision. All authors have read and approved the manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no conflict of interest.
Ethical approval
Not applicable.
Consent to participate
Not applicable.
Consent for publication
Not applicable.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Vuong, H.G., Dunn, I.F. Primary versus secondary gliosarcoma: a systematic review and meta-analysis. J Neurooncol 159, 195–200 (2022). https://doi.org/10.1007/s11060-022-04057-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-022-04057-w